These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 30666505)

  • 1. Immunotherapeutic Approaches for Multiple Myeloma: Where Are We Now?
    Htut M
    Curr Hematol Malig Rep; 2019 Feb; 14(1):1-10. PubMed ID: 30666505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Immunotherapies for Multiple Myeloma.
    D'Agostino M; Boccadoro M; Smith EL
    Curr Hematol Malig Rep; 2017 Aug; 12(4):344-357. PubMed ID: 28819882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Therapies in Multiple Myeloma.
    Kumar SK; Anderson KC
    Clin Cancer Res; 2016 Nov; 22(22):5453-5460. PubMed ID: 28151713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The challenges of checkpoint inhibition in the treatment of multiple myeloma.
    Paul B; Kang S; Zheng Z; Kang Y
    Cell Immunol; 2018 Dec; 334():87-98. PubMed ID: 30342750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in immunotherapy in multiple myeloma.
    Boussi L; Niesvizky R
    Curr Opin Oncol; 2017 Nov; 29(6):460-466. PubMed ID: 28877078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
    Podar K; Jager D
    Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for the treatment of multiple myeloma.
    Jung SH; Lee HJ; Vo MC; Kim HJ; Lee JJ
    Crit Rev Oncol Hematol; 2017 Mar; 111():87-93. PubMed ID: 28259300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma.
    Cohen AD; Raje N; Fowler JA; Mezzi K; Scott EC; Dhodapkar MV
    Clin Cancer Res; 2020 Apr; 26(7):1541-1554. PubMed ID: 31672768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma.
    Castella M; Fernández de Larrea C; Martín-Antonio B
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30445802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for multiple myeloma: Current status and future directions.
    Ayed AO; Chang LJ; Moreb JS
    Crit Rev Oncol Hematol; 2015 Dec; 96(3):399-412. PubMed ID: 26153389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy in multiple myeloma: when, where, and for who?
    Verkleij CPM; Korst CLBM; van de Donk NWCJ
    Curr Opin Oncol; 2020 Nov; 32(6):664-671. PubMed ID: 32852308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors.
    Gay F; D'Agostino M; Giaccone L; Genuardi M; Festuccia M; Boccadoro M; Bruno B
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):471-478. PubMed ID: 28689001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitors for the treatment of myeloma: novel investigational options.
    Le Calvez B; Moreau P; Touzeau C
    Expert Opin Investig Drugs; 2021 Sep; 30(9):965-973. PubMed ID: 34253136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current developments in immunotherapy in the treatment of multiple myeloma.
    Köhler M; Greil C; Hudecek M; Lonial S; Raje N; Wäsch R; Engelhardt M
    Cancer; 2018 May; 124(10):2075-2085. PubMed ID: 29409124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications.
    Susanibar Adaniya SP; Cohen AD; Garfall AL
    Am J Hematol; 2019 May; 94(S1):S28-S33. PubMed ID: 30730071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular immunotherapy as a therapeutic approach in multiple myeloma.
    Liegel J; Avigan D; Rosenblatt J
    Expert Rev Hematol; 2018 Jul; 11(7):525-536. PubMed ID: 29856648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging immune targets for the treatment of multiple myeloma.
    Sohail A; Mushtaq A; Iftikhar A; Warraich Z; Kurtin SE; Tenneti P; McBride A; Anwer F
    Immunotherapy; 2018 Feb; 10(4):265-282. PubMed ID: 29421983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update.
    Cohen AD
    Am Soc Clin Oncol Educ Book; 2018 May; 38():e6-e15. PubMed ID: 30231373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.